
    
      This is a multicentre randomised controlled clinical trial conducted in China to compare the
      effectiveness and safety of Anlotinib Plus Docetaxel in patients of EGFR wild-type Advanced
      Non-squamous Non-small Cell Lung Cancer.

      Eligible patients will be randomized to arm A and arm B:

      Arm A: Patients on the anlotinib and docetaxel arm received 75mg/m2 docetaxel as intravenous
      infusion on day 1 of a 21-day cycle and 12mg anlotinib orally daily on day 1to 14 of a 21-day
      cycle.

      Arm B: Patients on the docetaxel arm received 75mg/m2 docetaxel as intravenous infusion on
      day 1 of a 21-day cycle.
    
  